Welcome to our dedicated page for Brainsway Ltd. news (Ticker: BWAY), a resource for investors and traders seeking the latest updates and insights on Brainsway Ltd. stock.
BrainsWay Ltd (BWAY) delivers innovative neurostimulation solutions through its FDA-cleared Deep TMS technology, offering noninvasive treatment for mental health disorders. This news hub provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and corporate developments.
Access timely information about earnings reports, research collaborations, and therapeutic applications of Deep TMS technology. Our curated collection features official press releases and verified news covering treatment efficacy studies, global expansion efforts, and strategic partnerships.
Discover updates on BrainsWay's progress in addressing major depressive disorder, OCD, and addiction treatment through its patented magnetic stimulation platform. The resource serves investors monitoring neurotechnology trends and clinicians seeking evidence-based therapeutic innovations.
Bookmark this page for structured access to BWAY's latest developments in neuromodulation science and mental health treatment advancements. Stay informed about breakthrough clinical data and operational updates from this leader in noninvasive brain stimulation solutions.
BrainsWay reported a 37% year-over-year revenue growth in Q1 2024, achieving positive net income for the second consecutive quarter. The company also recorded positive Adjusted EBITDA and cash flow from operations for the third consecutive quarter. Revenues reached $9.1 million, with a gross margin of 75%. Operating income was $0.1 million compared to a loss of $3.7 million in the same period last year. Net income was $0.1 million, an improvement from a net loss of $2.4 million in Q1 2023. The Company's cash, cash equivalents, and short-term deposits stood at $47.8 million as of March 31, 2024. BrainsWay shipped 57 Deep TMS™ systems in Q1 2024, bringing the total installed base to 1,158 systems. Collaboration with partner Katie’s Way Plus expanded, and the Company installed its 11th Deep TMS system in Israel. With strong Q1 results, BrainsWay reaffirmed its full-year 2024 revenue guidance of $37 million to $40 million, expecting continued growth and profitability throughout the year.
FAQ
What is the current stock price of Brainsway Ltd. (BWAY)?
What is the market cap of Brainsway Ltd. (BWAY)?
